Valeant was too aggressive in dramatically raising the prices of some of its drugs, the company’s outgoing CEO Michael Pearson told a Senate committee, while its newest board member promised swift changes.
WSJ.com: Health, Wall Street Journal: Business: Health
Wed, 04/27/2016 - 7:47pm
Valeant was too aggressive in dramatically raising the prices of some of its drugs, the company’s outgoing CEO Michael Pearson told a Senate committee, while its newest board member promised swift changes.